Pancreatic Ductal Adenocarcinoma

• CLINICAL_TRIALS withdrawal · 2025-12-24
  Clinical Trial Update: STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma [Phase 1]

  A Phase 1 study of STIL101 for injection across pancreatic ductal adenocarcinoma, colorectal cancer, renal cell carcinoma, cervical cancer, …

• CLINICAL_TRIALS withdrawal · 2025-09-04
  Clinical Trial Update: PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9 [Phase 1]

  Phase 1 trial evaluating PET imaging agents 64Cu-Tz-SarAr and hu5B1-TCO in pancreatic, colorectal, and bladder cancers (including cancers wi…

• CLINICAL_TRIALS withdrawal · 2025-06-06
  Clinical Trial Update: Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC [Phase 1, Phase 2]

  Lisata Therapeutics reports that the Phase 1b/2a continuous infusion trial of ceretpetide in pancreatic ductal adenocarcinoma has been withd…

• CLINICAL_TRIALS withdrawal · 2025-05-02
  Clinical Trial Update: Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy

  A clinical trial investigating patient-derived cancer cell lines in untreated pancreatic ductal adenocarcinoma treated with gemcitabine-base…

• CLINICAL_TRIALS withdrawal · 2025-04-29
  Clinical Trial Update: CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer [Phase 2]

  A Phase 2 trial evaluating CPI-613 (devimistat) in combination with modified FOLFIRINOX for locally advanced pancreatic ductal adenocarcinom…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS withdrawal · 2025-01-17
  Clinical Trial Update: FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma [Phase 1]

  A Phase 1 trial of FL118 for pancreatic ductal adenocarcinoma has been withdrawn from the study.

• CLINICAL_TRIALS withdrawal · 2024-07-19
  Clinical Trial Update: Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma [Phase 2]

  Phase 2 study of Onvansertib in combination with gemcitabine and nab-paclitaxel for locally advanced, unresectable, or metastatic pancreatic…

• CLINICAL_TRIALS withdrawal · 2019-01-29
  Clinical Trial Update: Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy [Phase 4]

  This trial update reports the withdrawal of a Phase 4 study evaluating Albis for prevention of upper gastrointestinal hemorrhage in patients…

• CLINICAL_TRIALS withdrawal · 2016-06-09
  Clinical Trial Update: A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer [NA]

  The clinical trial investigating LDE225 (sonidegib) as a biomarker-driven treatment for resectable pancreatic cancer has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2015-01-09
  Clinical Trial Update: Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer [Phase 1]

  A Phase 1 trial combining dovitinib lactate, gemcitabine hydrochloride, and paclitaxel albumin-stabilized nanoparticle formulation for advan…